知搜-全球专利检索

  1. 登录
  2. 注册

搜索结果

15 条记录 (耗时 0.021 秒)

    Method for treating a pathological condition involving the activation or proliferation of CD127 positive cells with an anti-CD127 antibody
    11.
    发明授权
    Method for treating a pathological condition involving the activation or proliferation of CD127 positive cells with an anti-CD127 antibody 有权

    公开(公告)号：US11440964B2

    公开(公告)日：2022-09-13

    申请号：US16532000

    申请日：2019-08-05

    申请人： OSE IMMUNOTHERAPEUTICS

    发明人： Nicolas Poirier ,  Caroline Mary ,  Bernard Vanhove

    IPC分类号： A61K39/00 ,  C07K16/28 ,  G01N33/50 ,  G01N33/68

    摘要： The invention relates to antibodies directed against CD127, the alpha chain of the interleukin 7 (IL-7) receptor IL-7R), and which have antagonist properties for IL-7-IL-7R interaction, may present cytotoxic activity against CD127 positive cells but do not increase the maturation of dendritic cells (DCs) induced by TSLP, a cytokine also using CD127 as part of its receptor. Alternatively, or in addition, these antibodies do not induce the internalization of CD127 and/or inhibit the IL7-induced internalization of CD127. According to another aspect of the invention antibodies are provided which recognize a human CD127 epitope comprising sequences from the 2b site of CD127, in particular the epitope comprising comprises the human CD127 sequences of domain D1 and of the 2b site of CD127, in particular the epitope comprises at least one sequence from D1 comprising SEQ ID No: 115 (in particular comprising SEQ ID No: 110) and/or SEQ ID No: 111 and/or a sequence from the 2b site comprising the sequence of SEQ ID No: 116 and optionally also comprises SEQ ID No: 117 (in particular comprises SEQ ID No: 111). The antibodies of the invention are suitable for use in order to remedy to a condition diagnosed in a human patient which results from pathogenesis related to lymphopoiesis, when IL-7 signalling pathways provide contribution to said pathogenesis, especially when an increase in the maturation, more precisely the upregulation of costimulatory molecules, of dendritic cells is undesirable.

    Antibodies directed against CD127
    13.
    发明授权
    Antibodies directed against CD127 有权

    公开(公告)号：US10428152B2

    公开(公告)日：2019-10-01

    申请号：US15317355

    申请日：2015-06-10

    申请人： OSE IMMUNOTHERAPEUTICS

    发明人： Nicolas Poirier ,  Caroline Mary ,  Bernard Vanhove

    IPC分类号： C07K16/28 ,  C12N15/63 ,  G01N33/50 ,  A61K39/00

    摘要： The invention relates to antibodies directed against CD127, the alpha chain of the interleukin 7 (IL-7) receptor IL-7R), and which have antagonist properties for IL-7-IL-7R interaction, may present cytotoxic activity against CD127 positive cells but do not increase the maturation of dendritic cells (DCs) induced by TSLP, a cytokine also using CD127 as part of its receptor. Alternatively, or in addition, these antibodies do not induce the internalization of CD127 and/or inhibit the IL7-induced internalization of CD127. According to another aspect of the invention antibodies are provided which recognize a human CD127 epitope comprising sequences from the 2b site of CD127, in particular the epitope comprising comprises the human CD127 sequences of domain D1 and of the 2b site of CD127, in particular the epitope comprises at least one sequence from D1 comprising SEQ ID No: 115 (in particular comprising SEQ ID No: 10) and/or SEQ ID No: 111 and/or a sequence from the 2b site comprising the sequence of SEQ ID No: 116 and optionally also comprises SEQ ID No: 117 (in particular comprises SEQ ID No: 111). The antibodies of the invention are suitable for use in order to remedy to a condition diagnosed in a human patient which results from pathogenesis related to lymphopoiesis, when IL-7 signalling pathways provide contribution to said pathogenesis, especially when an increase in the maturation, more precisely the upregulation of costimulatory molecules, of dendritic cells is undesirable.